Evidence map›Paper›PMID 31316599›Full record

ArticleExperimental and therapeutic medicine2019

Aberrant expression and mechanism of miR-130b-3p/phosphatase and tensin homolog in nephroblastoma in children.

Yifeng Hu, Jingtie Yan

RetractedOpen access · diamondAbstract readRetracted Publication
In one paragraph

Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yifeng HuDepartment of Pediatric Surgery, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277102, P.R. China.
Jingtie YanDepartment of Pediatric Surgery, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277102, P.R. China.
Zaozhuang Municipal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nephroblastoma is the most common renal tumor in children. Abnormal expression of microRNAs (miRs) has been reported to be involved in the progression of various types of cancers. However, the role and underlying mechanism of miR-130b-3p in nephroblastoma remains unknown. Therefore, the present study aimed to explore the role and possible mechanism of miR-130b-3p in nephroblastoma in children. The present study identified that miR-130b-3p was highly expressed in nephroblastoma tissues obtained from children with nephroblastoma. To better understand the functions and the molecular mechanisms of miR-130b-3p in nephroblastoma, TargetScan was used to identify the potential targets of miR-130b-3p. Phosphatase and tensin homolog (PTEN), was identified as a target gene of miR-130b-3p, and it was observed to be downregulated in nephroblastoma. Further analysis indicated that miR-130b-3p inhibitor could significantly reduce cell proliferation, induce apoptosis and suppress the Akt/nuclear factor-κB/survivin signaling pathway in nephroblastoma cells. Notably, all these effects of miR-130b-3p on nephroblastoma cells were reversed by PTEN-small interfering RNA. In summary, the present study suggested that the miR-130b-3p/PTEN axis could serve a critical role in the progression and development of nephroblastoma. It also suggests that miR-130b-3p might be a valuable clinical biomarker and therapeutic target for nephroblastoma in children.

Indexed as

apoptosismicroRNA-130b-3pnephroblastomaphosphatase and tensin homolog

Identifiers

PMID31316599
PMCPMC6601369
OpenAlexW2948487902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.